A phase 3 clinical trial is
starting in the UK to evaluate an investigational mRNA vaccine candidate against H5 bird flu. The study will evaluate immune response, safety, and tolerability after two vaccine doses in adults aged 18 years and older. Around 4,000 healthy adults will take part across the UK and the United States. The trial will contribute data on the potential role of this vaccine candidate in pandemic preparedness.
English
Japanese
